^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    drebuxelimab (AK119)

    i
    Other names: AK119, AK 119
    Associations

    News

    Trials
    Company:
    Akesobio
    Drug class:
    CD73 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Akeso | Not yet recruiting --> Recruiting | N=72 --> 170 | Trial completion date: Jul 2025 --> Aug 2026 | Trial primary completion date: May 2024 --> May 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)
    9ms
    A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=23, Completed, Akeso | Active, not recruiting --> Completed | Phase classification: P1a/1b --> P1
    Trial completion • Phase classification
    |
    Kaitanni (cadonilimab) • drebuxelimab (AK119)
    10ms
    Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Terminated, Akeso | N=102 --> 33 | Trial completion date: Sep 2024 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Mar 2024 --> May 2024; Development strategy adjustment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Kaitanni (cadonilimab) • drebuxelimab (AK119)
    over1year
    Study of AK119 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=16, Completed, Akeso | Recruiting --> Completed | N=48 --> 16
    Trial completion • Enrollment change • Metastases
    |
    drebuxelimab (AK119)
    over2years
    Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, Akeso
    New P1/2 trial
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    PD-L1 expression • MSH6 expression
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)